Page 5 - CUAJFeb2023
P. 5

TABLE OF CONTENTS





       44 Accuracy of germ cell tumor histology and           RESIDENTS’ ROOM
       stage within a Canadian cancer registry                64 Patient and practitioner expectations for
       P Holland, E. Karmas, J. Merrimen, L.A. Wood           treatment of non-obstructive azoospermia
        .
       Cite as: Can Urol Assoc J 2023;17(2):44-8. http://dx.doi. org/10.5489/  J. Wong, S. Sparanese, L. Witherspoon, R. Flannigan
       cuaj.8030
                                                              Cite as: Can Urol Assoc J 2023;17(2):64-8. http://dx.doi. org/10.5489/
                                                              cuaj.8027
       49 Predictors of prostate                              Appendix available at cuaj.ca
       cancer survivors’ engagement
       in self-management behaviors                           RESEARCH LETTER
       E. Giannopoulos, C. Catton, M.E. Giuliani, E. Kucharski,
       A. Matthew, N.K. Quartey, J. Papadakos                 69 Analyzing the growth in social media

       Cite as: Can Urol Assoc J 2023;17(2):49-60. http://dx.doi. org/10.5489/  proliferation in academic urology
       cuaj.7982                                              M. Zaliznyak, K. Tsai, T.W. Gaither, R. Wong, B. Duel, Z. Hamilton
       Appendix available at cuaj.ca                          Cite as: Can Urol Assoc J 2023;17(2):69-71. http://dx.doi. org/10.5489/
                                                              cuaj.8038
       SPECIAL COMMENTARY

       61 An environmental scan of sexual health              IN MEMORIAM
       services for cancer survivors among Canadian           72 G. John Ankenman
       institutions                                           Cite as: Can Urol Assoc J 2023;17(2):72. http://dx.doi.org/10.5489/
       R. Flannigan, A. Matthew, S. Sparanese, E. Wu, S. Guirguis,    cuaj.8243
       M. Sundar, F. Saad, A. Loblaw, J. Nargi, L. Witherspoon, C. Canil,
       R.A. Rendon, L. Labelle, J. Turner, C. Higano
       Cite as: Can Urol Assoc J 2023;17(2):61-3. http://dx.doi.org/10.5489/
       cuaj.8093




         Advertisers’ Index                            Astellas                  PSFDH
         Index des announceurs                         Myrbetriq, Page 9         Classified, Page 4
                                                       Oncology, Page 2
                                                                                 Szio+
                                                       Bayer                     Utiva, Page 10
                                                       Nubeqa, Inside Front Cover
                                                       Xofigo, Inside Back Cover,
 This is how we define                                 Outside Back Cover

 clinically meaningful

 Outcomes that matter to patients

 By developing novel targeted therapies, supporting promising
 research, and forming strategic collaborations with all members
 of the cancer community, Astellas Oncology is dedicated to
 moving cancer treatment forward for patients AND their
 loved ones.

 Learn more at astellas.ca


 © 2022 Astellas Pharma Canada, Inc. All rights reserved.
 XTD_2021_0209_CA EN 08/2021
                                                                           CUAJ  •  FEBRUARY 2023  •  VOLUME 17, ISSUE 2  3




 22173b_AstellasOncWeddingAdEN_REL_C00_00_.indd   1  2022-07-26   4:45 PM
   1   2   3   4   5   6   7   8   9   10